Minocycline Foam (Zilxi) for Rosacea

Date: November 16, 2020
Issue #: 
1611Summary: 
The FDA has approved a 1.5% topical foam formulation
of minocycline (Zilxi– Foamix) for treatment of
inflammatory lesions of rosacea in adults. It is
the only topical minocycline product approved for
this indication. The same manufacturer markets
minocycline foam 4%(Amzeeq) for treatment of acne
in patients≥9 years old.

Source: The Medical Letter - November 6, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research